IDCT for Lumbar Disc Degeneration - Medical / Health Care
The first product candidate to utilize the Discogenic Cell platform is IDCT (rebonuputemcel).
-
Most popular related searches
Details
IDCT is an allogeneic (donor-derived), non-invasive cell therapy that is being evaluated in two concurrent clinical trials in the U.S. and Japan for the treatment of adult patients with single-level mild to moderate symptomatic lumbar disc degeneration.
During treatment, a single dose of IDCT is injected into the painful disc percutaneously (non-surgically).
Based on preclinical experience with IDCT, we hypothesize that the result will be reduced pain and disability.